Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AFMD Affimed NV > Detailed Quotes

AFMD Affimed NV

2.060
+0.030+1.48%
Close 09/30 16:00 ET
2.0600.0000.00%
Post Mkt Price 09/30 16:03 ET
High
2.220
Open
2.030
Turnover
2.44M
Low
2.030
Pre Close
2.030
Volume
1.15M
Market Cap
307.64M
P/E(TTM)
Loss
52wk High
7.350
Shares
149.34M
P/E(Static)
Loss
52wk Low
1.930
Float Cap
256.34M
Bid/Ask %
42.86%
Historical High
24.200
Shs Float
124.44M
Volume Ratio
1.23
Historical Low
1.150
Dividend TTM
--
Div Yield TTM
--
P/B
1.53
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.92%
Amplitude
9.36%
Avg Price
2.131
Lot Size
1
Float Cap
256.34M
Bid/Ask %
42.86%
Historical High
24.200
Shs Float
124.44M
Volume Ratio
1.23
Historical Low
1.150
Dividend TTM
--
P/B
1.53
Dividend LFY
--
Turnover Ratio
0.92%
Amplitude
9.36%
Avg Price
2.131
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
CEO: Dr. Adi Hoess
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...